600216 浙江医药
交易中 08-04 14:31:37
资讯
新帖
简况
每周股票复盘：浙江医药（600216）拟回购1-2亿元股份
证券之星 · 07-26
每周股票复盘：浙江医药（600216）拟回购1-2亿元股份
浙江医药（600216）披露以集中竞价交易方式回购股份的回购报告书，7月20日股价上涨1.9%
证券之星 · 07-20
浙江医药（600216）披露以集中竞价交易方式回购股份的回购报告书，7月20日股价上涨1.9%
每周股票复盘：浙江医药（600216）拟回购1至2亿元股份
证券之星 · 07-19
每周股票复盘：浙江医药（600216）拟回购1至2亿元股份
浙江医药（600216）披露回购股份事项前十大股东持股情况，7月17日股价下跌3.97%
证券之星 · 07-17
浙江医药（600216）披露回购股份事项前十大股东持股情况，7月17日股价下跌3.97%
浙江医药（600216）披露以集中竞价交易方式回购股份方案，7月14日股价上涨2.35%
证券之星 · 07-14
浙江医药（600216）披露以集中竞价交易方式回购股份方案，7月14日股价上涨2.35%
每周股票复盘：浙江医药（600216）国投高科减持计划届满未减持
证券之星 · 07-12
每周股票复盘：浙江医药（600216）国投高科减持计划届满未减持
浙江医药（600216）披露持股5%以上股东减持计划届满暨未减持股份公告，7月7日股价下跌5.84%
证券之星 · 07-07
浙江医药（600216）披露持股5%以上股东减持计划届满暨未减持股份公告，7月7日股价下跌5.84%
7月7日浙江医药跌5.84%，天弘医疗健康混合A基金重仓该股
证券之星 · 07-07
7月7日浙江医药跌5.84%，天弘医疗健康混合A基金重仓该股
每周股票复盘：浙江医药（600216）新码生物递表港交所拟上市
证券之星 · 07-05
每周股票复盘：浙江医药（600216）新码生物递表港交所拟上市
浙江医药（600216）披露2025年年度权益分派实施公告，7月2日股价上涨1.7%
证券之星 · 07-02
浙江医药（600216）披露2025年年度权益分派实施公告，7月2日股价上涨1.7%
股市必读：浙江医药（600216）6月30日董秘有最新回复
证券之星 · 07-01
股市必读：浙江医药（600216）6月30日董秘有最新回复
浙江医药：关于公司直接定向回购特定股东股份的建议，目前相关法律法规尚不支持相关交易方式
证券之星 · 06-30
浙江医药：关于公司直接定向回购特定股东股份的建议，目前相关法律法规尚不支持相关交易方式
浙江医药：关于子公司新码生物ARX788项目进展
证券之星 · 06-30
浙江医药：关于子公司新码生物ARX788项目进展
浙江医药：关于子公司新码生物ARX788项目进展
证券之星 · 06-30
浙江医药：关于子公司新码生物ARX788项目进展
浙江医药：公司的主要产品中并不包含您提问中的相关产品
证券之星 · 06-30
浙江医药：公司的主要产品中并不包含您提问中的相关产品
浙江医药：公司始终高度重视市值管理工作
证券之星 · 06-30
浙江医药：公司始终高度重视市值管理工作
浙江医药：子公司新码生物向港交所递交上市申请
格隆汇 · 06-29
浙江医药：子公司新码生物向港交所递交上市申请
每周股票复盘：浙江医药（600216）制定董高薪酬管理制度
证券之星 · 06-07
每周股票复盘：浙江医药（600216）制定董高薪酬管理制度
浙江医药（600216）披露《董事、高级管理人员薪酬管理制度》，6月2日股价下跌1.47%
证券之星 · 06-02
浙江医药（600216）披露《董事、高级管理人员薪酬管理制度》，6月2日股价下跌1.47%
每周股票复盘：浙江医药（600216）出资6000万参与创投基金
证券之星 · 05-31
每周股票复盘：浙江医药（600216）出资6000万参与创投基金
加载更多
公司概况
公司名称：
浙江医药股份有限公司
所属行业：
医药制造业
上市日期：
1999-10-21
主营业务：
浙江医药股份有限公司的主营业务是药品与生命营养品的研发、生产和销售以及药品流通。公司的主要产品是维生素、类维生素产品、抗耐药抗生素、抗疟疾类、喹诺酮、抗耐药抗生素、降糖类、激素类、叶黄素、天然维生素E、辅酶Q10、医药商业。公司入选首批浙江省制造业单项冠军企业、浙江省第一批先进级智能工厂。
发行价格：
5.16
{"stockData":{"symbol":"600216","market":"SH","secType":"STK","nameCN":"浙江医药","latestPrice":12.24,"timestamp":1785825097000,"preClose":12.26,"halted":0,"volume":11257100,"delay":0,"changeRate":-0.0016,"floatShares":951000000,"shares":961999999,"eps":0.7813,"marketStatus":"交易中","change":-0.02,"latestTime":"08-04 14:31:37","open":12.34,"high":12.39,"low":12.19,"amount":138000000,"amplitude":0.0163,"askPrice":12.25,"askSize":237,"bidPrice":12.24,"bidSize":376,"shortable":0,"etf":0,"ttmEps":0.7813,"tradingStatus":2,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1785826800000},"marketStatusCode":2,"adr":0,"adjPreClose":12.26,"symbolType":"stock","openAndCloseTimeList":[[1785807000000,1785814200000],[1785819600000,1785826800000]],"highLimit":13.49,"lowLimit":11.03,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":961637750,"isCdr":false,"pbRate":1.05,"roa":"--","peRate":15.666197,"roe":"2.59%","epsLYR":0.91,"committee":0.251898,"marketValue":11770000000,"turnoverRate":0.0118,"status":1,"floatMarketCap":11645000000},"requestUrl":"/m/hq/s/600216","defaultTab":"news","newsList":[{"id":"2654052252","title":"每周股票复盘：浙江医药（600216）拟回购1-2亿元股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2654052252","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2654052252?lang=zh_cn&edition=full","pubTime":"2026-07-26 01:47","pubTimestamp":1785001632,"startTime":"0","endTime":"0","summary":"截至2026年7月24日收盘，浙江医药报收于11.63元，较上周的12.09元下跌3.8%。本周，浙江医药7月21日盘中最高价报12.44元。公司公告汇总浙江医药发布以集中竞价交易方式回购股份的报告书，拟回购资金总额不低于1亿元且不超过2亿元，资金来源于自有资金或自筹资金。公司已获得工商银行不超过1.8亿元的股票回购专项贷款承诺。回购股份将用于员工持股计划或股权激励。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072600000380.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0191","BK0239","BK0028","BK0188","600216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652717291","title":"浙江医药（600216）披露以集中竞价交易方式回购股份的回购报告书，7月20日股价上涨1.9%","url":"https://stock-news.laohu8.com/highlight/detail?id=2652717291","media":"证券之星","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2652717291?lang=zh_cn&edition=full","pubTime":"2026-07-20 17:40","pubTimestamp":1784540418,"startTime":"0","endTime":"0","summary":"截至2026年7月20日收盘，浙江医药报收于12.32元，较前一交易日上涨1.9%，最新总市值为118.47亿元。近日，浙江医药发布《关于以集中竞价交易方式回购股份的回购报告书》。公告显示，公司拟以集中竞价交易方式回购股份，资金总额不低于1亿元且不超过2亿元，资金来源为自有资金或自筹资金，其中已获工商银行不超过1.8亿元的股票回购专项贷款承诺。回购股份价格不超过17.90元/股，回购期限为董事会审议通过之日起不超过12个月。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072000027175.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0188","BK0028","600216","BK0191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652423726","title":"每周股票复盘：浙江医药（600216）拟回购1至2亿元股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2652423726","media":"证券之星","labels":["buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2652423726?lang=zh_cn&edition=full","pubTime":"2026-07-19 01:48","pubTimestamp":1784396893,"startTime":"0","endTime":"0","summary":"截至2026年7月17日收盘，浙江医药报收于12.09元，较上周的11.83元上涨2.2%。本周，浙江医药7月16日盘中最高价报12.74元。本周关注点公司公告汇总：浙江医药拟使用1亿元至2亿元回购股份，用于员工持股或股权激励。公司公告汇总浙江医药于2026年7月14日召开第十届十三次董事会会议，审议通过《关于以集中竞价交易方式回购股份的议案》。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071900000392.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600216","BK0191","BK0028","BK0188","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652289807","title":"浙江医药（600216）披露回购股份事项前十大股东持股情况，7月17日股价下跌3.97%","url":"https://stock-news.laohu8.com/highlight/detail?id=2652289807","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2652289807?lang=zh_cn&edition=full","pubTime":"2026-07-17 22:16","pubTimestamp":1784297775,"startTime":"0","endTime":"0","summary":"截至2026年7月17日收盘，浙江医药报收于12.09元，较前一交易日下跌3.97%，最新总市值为116.26亿元。该股当日开盘12.5元，最高12.64元，最低12.09元，成交额达3.12亿元，换手率为2.67%。近日，浙江医药发布《关于回购股份事项前十大股东和前十大无限售条件股东持股情况的公告》。前十大股东中，新昌县昌欣投资发展有限公司持股208,192,361股，占比21.65%；国投高科技投资有限公司持股150,127,573股，占比15.61%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071700044725.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0239","BK0191","600216","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651104650","title":"浙江医药（600216）披露以集中竞价交易方式回购股份方案，7月14日股价上涨2.35%","url":"https://stock-news.laohu8.com/highlight/detail?id=2651104650","media":"证券之星","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651104650?lang=zh_cn&edition=full","pubTime":"2026-07-14 22:23","pubTimestamp":1784038992,"startTime":"0","endTime":"0","summary":"截至2026年7月14日收盘，浙江医药报收于12.17元，较前一交易日上涨2.35%，最新总市值为117.03亿元。近日，浙江医药发布《关于以集中竞价交易方式回购股份方案的公告》。公告显示，公司拟以集中竞价交易方式回购股份，回购金额不低于1亿元且不超过2亿元，资金来源为自有资金或自筹资金，其中包括工商银行提供的不超过1.8亿元专项贷款。回购股份拟用于员工持股计划或股权激励。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071400049633.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0191","600216","BK0239","BK0188","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650154891","title":"每周股票复盘：浙江医药（600216）国投高科减持计划届满未减持","url":"https://stock-news.laohu8.com/highlight/detail?id=2650154891","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2650154891?lang=zh_cn&edition=full","pubTime":"2026-07-12 01:57","pubTimestamp":1783792628,"startTime":"0","endTime":"0","summary":"截至2026年7月10日收盘，浙江医药报收于11.83元，较上周的12.29元下跌3.74%。本周，浙江医药7月6日盘中最高价报12.95元。公司于2026年3月17日披露，国投高科拟通过集中竞价交易方式减持不超过9,616,377股，即不超过公司总股本的1%。减持期间为2026年4月8日至2026年7月7日。截至2026年7月7日，国投高科未实施减持，减持计划时间届满，持股数量和比例不变，仍为150,127,573股，占总股本的15.61%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071200000519.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0191","600216","BK0028","BK0188","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649793694","title":"浙江医药（600216）披露持股5%以上股东减持计划届满暨未减持股份公告，7月7日股价下跌5.84%","url":"https://stock-news.laohu8.com/highlight/detail?id=2649793694","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2649793694?lang=zh_cn&edition=full","pubTime":"2026-07-07 23:04","pubTimestamp":1783436656,"startTime":"0","endTime":"0","summary":"截至2026年7月7日收盘，浙江医药报收于12.1元，较前一交易日下跌5.84%，最新总市值为116.36亿元。近日，浙江医药发布《持股5%以上股东减持计划届满暨未减持股份的公告》。公司于2026年3月17日披露，国投高科拟通过集中竞价交易方式减持不超过9,616,377股，即不超过公司总股本的1%。减持期间为2026年4月8日至2026年7月7日。截至2026年7月7日，国投高科未实施减持，减持计划时间届满，持股数量和比例不变，仍为150,127,573股，占总股本的15.61%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070700042325.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0239","BK0191","BK0028","600216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649001686","title":"7月7日浙江医药跌5.84%，天弘医疗健康混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2649001686","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2649001686?lang=zh_cn&edition=full","pubTime":"2026-07-07 16:20","pubTimestamp":1783412407,"startTime":"0","endTime":"0","summary":"证券之星消息，7月7日浙江医药跌5.84%，收盘报12.1元，换手率3.33%，成交量31.68万手，成交额3.9亿元。重仓浙江医药的前十大公募基金请见下表：该股最近90天内共有2家机构给出评级，买入评级2家。根据2026基金Q1季报公募基金重仓股数据，重仓该股的公募基金共14家，其中持有数量最多的公募基金为天弘基金的天弘医疗健康混合A。天弘医疗健康混合A的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070700026715.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","159760","BK0028","BK0191","600216","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649694579","title":"每周股票复盘：浙江医药（600216）新码生物递表港交所拟上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2649694579","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2649694579?lang=zh_cn&edition=full","pubTime":"2026-07-05 02:00","pubTimestamp":1783188044,"startTime":"0","endTime":"0","summary":"截至2026年7月3日收盘，浙江医药报收于12.29元，较上周的11.29元上涨8.86%。本周，浙江医药7月3日盘中最高价报12.32元。公司公告汇总浙江医药拟分拆子公司新码生物至香港联交所主板上市。2026年6月29日，新码生物已通过保密形式向香港联交所递交H股发行上市申请文件。浙江医药因公司回购专用证券账户持有3,479,200股不参与利润分配，2025年度利润分配实施差异化分红。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070500000477.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","HEXmain","BK0028","BK0191","600216","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648857756","title":"浙江医药（600216）披露2025年年度权益分派实施公告，7月2日股价上涨1.7%","url":"https://stock-news.laohu8.com/highlight/detail?id=2648857756","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648857756?lang=zh_cn&edition=full","pubTime":"2026-07-02 22:34","pubTimestamp":1783002857,"startTime":"0","endTime":"0","summary":"截至2026年7月2日收盘，浙江医药报收于11.99元，较前一交易日上涨1.7%，最新总市值为115.3亿元。该股当日开盘11.8元，最高12.09元，最低11.73元，成交额达2.58亿元，换手率为2.27%。近日，浙江医药发布《2025年年度权益分派实施公告》：每股现金红利0.28元（含税），股权登记日为2026年7月8日，除权（息）日为2026年7月9日，现金红利发放日为2026年7月9日。本次利润分配以总股本扣除回购股份后的958,158,550股为基数，合计派发现金红利268,284,394.00元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070200042284.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0239","600216","BK0191","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648556620","title":"股市必读：浙江医药（600216）6月30日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2648556620","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648556620?lang=zh_cn&edition=full","pubTime":"2026-07-01 02:48","pubTimestamp":1782845292,"startTime":"0","endTime":"0","summary":"截至2026年6月30日收盘，浙江医药报收于11.4元，下跌2.65%，换手率1.65%，成交量15.68万手，成交额1.79亿元。公司公告汇总浙江医药关于分拆所属子公司浙江新码生物医药股份有限公司至香港联合交易所有限公司主板上市的进展公告浙江医药拟分拆子公司新码生物至香港联交所主板上市；2026年6月29日，新码生物已通过保密形式向香港联交所递交H股发行上市申请文件；本次分拆上市尚需获得中国证监会、香港证监会及香港联交所等批准。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070100001623.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","600216","BK0191","BK0188","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647512535","title":"浙江医药：关于公司直接定向回购特定股东股份的建议，目前相关法律法规尚不支持相关交易方式","url":"https://stock-news.laohu8.com/highlight/detail?id=2647512535","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2647512535?lang=zh_cn&edition=full","pubTime":"2026-06-30 16:09","pubTimestamp":1782806961,"startTime":"0","endTime":"0","summary":"证券之星消息，浙江医药(600216)06月30日在投资者关系平台上答复投资者关心的问题。投资者提问：对于二股东的行为已经无语了，公司可否考虑直接将他们的股份回购注销？一方面公司有这方面实力，一方面也可以增加大股东持股比例，再者可以直接提高每股业绩，请认真考虑！浙江医药回复：尊敬的投资者您好，关于公司直接定向回购特定股东股份的建议，目前相关法律法规尚不支持相关交易方式，公司管理层始终高度重视全体股东利益，感谢您的关注与建议。本文数据来源于上海证券交易所e互动，仅供参考不构成投资建议。责任编辑：刘浩然","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026063000027958.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0188","600216","BK0191","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647355755","title":"浙江医药：关于子公司新码生物ARX788项目进展","url":"https://stock-news.laohu8.com/highlight/detail?id=2647355755","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2647355755?lang=zh_cn&edition=full","pubTime":"2026-06-30 16:09","pubTimestamp":1782806952,"startTime":"0","endTime":"0","summary":"证券之星消息，浙江医药(600216)06月30日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘您好，想了解ARX788目前的审评最新进展，是否还有需要补充的资料？公司对该产品的获批时间是否有合理预期？获批后能否快速实现生产和销售？浙江医药回复：尊敬的投资者您好，关于子公司新码生物ARX788项目进展，若进展触及信披义务，公司将及时在上交所官网上披露。本文数据来源于上海证券交易所e互动，仅供参考不构成投资建议。责任编辑：刘浩然","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026063000027934.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0191","BK0028","BK0239","600216","150257"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647535578","title":"浙江医药：关于子公司新码生物ARX788项目进展","url":"https://stock-news.laohu8.com/highlight/detail?id=2647535578","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2647535578?lang=zh_cn&edition=full","pubTime":"2026-06-30 16:09","pubTimestamp":1782806948,"startTime":"0","endTime":"0","summary":"证券之星消息，浙江医药(600216)06月30日在投资者关系平台上答复投资者关心的问题。投资者提问：请问ARX788上市申请是否采用滚动提交方式？目前CDE是否已发出正式受理通知？浙江医药回复：尊敬的投资者您好，关于子公司新码生物ARX788项目进展，若进展触及信披义务，公司将及时在上交所官网上披露。本文数据来源于上海证券交易所e互动，仅供参考不构成投资建议。责任编辑：刘浩然","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026063000027927.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","600216","BK0239","150257","BK0191","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647355265","title":"浙江医药：公司的主要产品中并不包含您提问中的相关产品","url":"https://stock-news.laohu8.com/highlight/detail?id=2647355265","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2647355265?lang=zh_cn&edition=full","pubTime":"2026-06-30 16:06","pubTimestamp":1782806797,"startTime":"0","endTime":"0","summary":"证券之星消息，浙江医药(600216)06月30日在投资者关系平台上答复投资者关心的问题。投资者提问：您好，我想咨询一下公司**啤酒花提取物黄腐酚（黄腐粉）**的业务，目前是否已经量产？有没有对接国内保健品或饮料企业？浙江医药回复：尊敬的投资者您好，公司的主要产品中并不包含您提问中的相关产品，感谢您的关注。本文数据来源于上海证券交易所e互动，仅供参考不构成投资建议。责任编辑：刘浩然","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026063000027639.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0239","BK0191","600216","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647247533","title":"浙江医药：公司始终高度重视市值管理工作","url":"https://stock-news.laohu8.com/highlight/detail?id=2647247533","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2647247533?lang=zh_cn&edition=full","pubTime":"2026-06-30 15:51","pubTimestamp":1782805873,"startTime":"0","endTime":"0","summary":"证券之星消息，浙江医药06月30日在投资者关系平台上答复投资者关心的问题。公司难道没有市值管理的要求吗？公司管理层努力提升经营能力，开拓市场，开发产品，提升公司价值，但公司无法对股价或市值进行预期或承诺。关于投资者交流方面，公司一直以来高度重视投资者关系管理，严格按照监管规则履行信息披露义务及开展投资者关系工作。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026063000025415.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0239","BK0191","600216","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647932164","title":"浙江医药：子公司新码生物向港交所递交上市申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2647932164","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2647932164?lang=zh_cn&edition=full","pubTime":"2026-06-29 15:56","pubTimestamp":1782719805,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK0191","BK0239","600216","BK0028","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641127539","title":"每周股票复盘：浙江医药（600216）制定董高薪酬管理制度","url":"https://stock-news.laohu8.com/highlight/detail?id=2641127539","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2641127539?lang=zh_cn&edition=full","pubTime":"2026-06-07 02:16","pubTimestamp":1780769773,"startTime":"0","endTime":"0","summary":"截至2026年6月5日收盘，浙江医药报收于12.17元，较上周的12.76元下跌4.62%。本周，浙江医药6月1日盘中最高价报12.94元。浙江医药当前最新总市值117.03亿元，在化学制药板块市值排名41/150，在两市A股市值排名1717/5206。本周关注点公司公告汇总：浙江医药制定董高薪酬管理制度，绩效薪酬占比不低于50%公司公告汇总浙江医药股份有限公司制定了《董事、高级管理人员薪酬管理制度》，旨在完善公司治理，建立科学有效的激励与约束机制。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060700000630.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0188","600216","BK0191","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640289949","title":"浙江医药（600216）披露《董事、高级管理人员薪酬管理制度》，6月2日股价下跌1.47%","url":"https://stock-news.laohu8.com/highlight/detail?id=2640289949","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640289949?lang=zh_cn&edition=full","pubTime":"2026-06-02 22:24","pubTimestamp":1780410268,"startTime":"0","endTime":"0","summary":"截至2026年6月2日收盘，浙江医药报收于12.7元，较前一交易日下跌1.47%，最新总市值为122.13亿元。该股当日开盘12.89元，最高12.9元，最低12.65元，成交额达1.2亿元，换手率为0.99%。近日，浙江医药股份有限公司披露《董事、高级管理人员薪酬管理制度》。公告显示，该制度旨在完善公司治理，建立科学有效的激励与约束机制，适用于公司董事和高级管理人员。制度还明确了薪酬支付、绩效评价、追索止付等机制，并经公司董事会审议通过后提交股东会审议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060200047342.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0239","BK0191","BK0028","600216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639122604","title":"每周股票复盘：浙江医药（600216）出资6000万参与创投基金","url":"https://stock-news.laohu8.com/highlight/detail?id=2639122604","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2639122604?lang=zh_cn&edition=full","pubTime":"2026-05-31 03:39","pubTimestamp":1780169950,"startTime":"0","endTime":"0","summary":"截至2026年5月29日收盘，浙江医药报收于12.76元，较上周的13.61元下跌6.25%。本周，浙江医药5月25日盘中最高价报13.6元。浙江医药当前最新总市值122.7亿元，在化学制药板块市值排名42/150，在两市A股市值排名1669/5207。本周关注点公司公告汇总：浙江医药认缴6,000万元投资诸暨普华灼然创业投资合伙企业，占出资总额39.74%。公司本次投资不影响主营业务开展，但存在投资收益不确定及本金受损风险。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026053100001056.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0191","BK0239","600216","BK0028","BK0188"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1785825106468,"stockEarnings":[{"period":"1week","weight":0.0294},{"period":"1month","weight":0.0213},{"period":"3month","weight":-0.1367},{"period":"6month","weight":-0.1456},{"period":"1year","weight":-0.2125},{"period":"ytd","weight":-0.0944}],"compareEarnings":[{"period":"1week","weight":-0.0126},{"period":"1month","weight":-0.0579},{"period":"3month","weight":-0.0736},{"period":"6month","weight":-0.0713},{"period":"1year","weight":0.0701},{"period":"ytd","weight":-0.0401}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"浙江医药股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"51827人(较上一季度减少15.77%)","perCapita":"18357股","listingDate":"1999-10-21","address":"浙江省绍兴市越城区滨海新城致远中大道168号","registeredCapital":"96163万元","survey":" 浙江医药股份有限公司的主营业务是药品与生命营养品的研发、生产和销售以及药品流通。公司的主要产品是维生素、类维生素产品、抗耐药抗生素、抗疟疾类、喹诺酮、抗耐药抗生素、降糖类、激素类、叶黄素、天然维生素E、辅酶Q10、医药商业。公司入选首批浙江省制造业单项冠军企业、浙江省第一批先进级智能工厂。","listedPrice":5.16},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"浙江医药(600216)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供浙江医药(600216)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"浙江医药,600216,浙江医药股票,浙江医药股票老虎,浙江医药股票老虎国际,浙江医药行情,浙江医药股票行情,浙江医药股价,浙江医药股市,浙江医药股票价格,浙江医药股票交易,浙江医药股票购买,浙江医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"浙江医药(600216)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供浙江医药(600216)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}